Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 10/20 | 0.38 |
| ▸ | NPC1 | O15118 | 9/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285598 | 0.92 | GAA (0.41) | GAARAB9ANPC1KCNH2MCHR2 | |
| SCHEMBL13705283 | 0.86 | NPC1 (0.44) | GAARAB9ANPC1 | |
| SCHEMBL8125453 | 0.83 | ADRB1 (0.38) | GAARAB9ANPC1ADRB1KCNH2 | |
| SCHEMBL4289860 | 0.80 | GAA (0.41) | GAARAB9ANPC1 | |
| SCHEMBL4287230 | 0.80 | RAB9A (0.42) | GAARAB9ANPC1 | |
| SCHEMBL4290709 | 0.77 | GAA (0.42) | GAARAB9ANPC1KCNH2MCHR2 | |
| SCHEMBL4281841 | 0.75 | KMT2A (0.39) | RAB9ANPC1KCNH2MCHR1 | |
| SCHEMBL4293422 | 0.72 | SMN1; SMN2 (0.43) | GAA | |
| Hydrochloric Acid SCHEMBL4289031 | 0.72 | SMN1; SMN2 (0.43) | GAA | |
| SCHEMBL3935992 | 0.70 | GRIN2B (0.47) | RAB9ANPC1ADRB1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GAA 1381/4885RAB9A 1247/4885NPC1 1165/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GAA 1381/4885RAB9A 1247/4885NPC1 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.